In his more than 20 years in practice, Kevin Espinola has advised on M&A transactions with an aggregate value in excess of $150 billion. His practice focuses on mergers, acquisitions, divestitures, takeovers and takeover preparedness, restructurings, recapitalizations, securities transactions, activist defense, and corporate governance issues. Kevin also serves as primary outside counsel to several publicly traded corporations and privately owned companies, particularly in the life sciences (including pharmaceuticals, genetic testing, medical devices, and biologics), technology, and software industries.
Kevin's M&A practice includes public company mergers and tender offers, private company acquisitions and divestitures, hostile takeovers, multifaceted cross-border transactions (Asia in particular), and transactions involving SEC-registered contingent value rights and earn-outs. He also advises clients in connection with structured options to purchase entities or to purchase or license assets, including significant intellectual property. His governance experience includes advising companies and boards of directors regarding crisis management, risk management, takeover defense planning, shareholder activism, and multistakeholder governance. In addition, he serves as a trusted advisor to publicly traded companies in connection with their public company reporting obligations.
Kevin's current and prior representations include industry leaders such as Advantage Solutions, Ambry Genetics, Astellas Pharma, BioMarin, Celgene, Cylance, Epicor Software, Monolithic Power Systems, Monster Beverage, Oclaro, SAP, and TDK.
Experience
The following represents experience prior to joining Jones Day.
Advised Amgen Inc. in connection with its acquisition of Immunex Corporation ($16 billion)
Advised Amgen Inc. in connection with its acquisition of Tularik, Inc. ($1.3 billion)
Advised Axon Instruments, Inc. in connection with its sale to Molecular Devices Corporation ($140 million)
Advised Axonyx, Inc. in connection with its sale to TorreyPines Therapeutics, Inc. ($80 million)
Advised CIMA Labs Inc. in its terminated merger-of-equals transaction with aaiPharma Inc. ($900 million, combined value)
Advised CIMA Labs Inc. in connection with the sale of the company to Cephalon, Inc. ($515 million)
Advised FileNet Corporation in connection with its sale to IBM ($1.6 billion)
Advised First Consulting Group in connection with its sale to Computer Sciences Corporation ($365 million)
Advised Harrah’s Entertainment, Inc. in connection with its acquisition of Caesars Entertainment, Inc. ($9.44 billion)
Advised the controlling stockholders of Hydril Corporation in connection with the sale of the company to Tenaris S.A. ($2.16 billion)
Advised ICOS Corporation in connection with the sale of the company to Eli Lilly & Company ($2.3 billion)
Advised InSight Health Services Corp. in connection with the sale of the company to J.W. Childs Associates, L.P. and The Halifax Group, L.L.C. ($450 million) (represented special committee and the company)
Advised Interpore International, Inc. in connection with its sale to Biomet, Inc. ($280 million)
Advised IsoTis Inc. in connection with the sale of the company to Integra Life Sciences Holding Corporation ($51 million)
Advised Medicis Pharmaceutical Corporation in connections with its terminated acquisition of Inamed Corporation ($2.8 billion)
Advised Medicis Pharmaceutical Corporation in connections with the successful defense against hostile bid made by Mentor Corporation
Advised Micro Therapeutics, Inc in connection with the sale of the company to its controlling stockholder, ev3 Inc. (represented special committee)
Advised Ortel Corporation in connection its acquisition by Lucent Technologies Inc. ($2.95 billion)
Advised PIMCO Advisors, L.P. in connection with its acquisition of Oppenheimer Capital ($265 million)
Advised The Sands Regent in connection with the sale of the company to Herbst Gaming, Inc. ($148 million)
Advised Tuboscope, Inc. in connection with its merger-of-equals with Varco International, Inc. ($1.8 billion, combined value)
Advised Varco International, Inc in connection with its merger-of-equals with National-Oilwell, Inc. ($5 billion, combined value)
Advised Watson Pharmaceutical, Inc. in connection with its acquisition of Andrx Corporation ($1.9 billion)
Advised Advantage Sales & Marketing, LLC in connection with its recapitalization and acquisition of a majority interest by Allied Capital Corporation
Advised Ambassadors International, Inc. in connection with its acquisition of Bellingham Marine Industries, Inc. from Nishida Tekko Corporation
Advised Ambassadors International, Inc. in connection with its acquisition of Newport Harbor Shipyard II, Inc.
Advised Ambassadors International, Inc. in connection with its acquisition of BellPort Group, Inc. (represented special committee and company)
Advised Ambassadors International, Inc. in connection with its acquisition of BellJa Holding Company, Inc.
Advised Complete Production Services in connection with its acquisition of Pumpco Services, Inc.
Advised Harrah’s Entertainment, Inc. in connection with its acquisitions of Horseshoe Gaming Holding Corp.
Advised Innovent Systems, Inc. in connection with the sale of the company to Broadcom Corporation
- University of Notre Dame (J.D. magna cum laude 1997); University of California, Irvine (B.A. 1993)
- California